Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 March 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Changing burden of Hepatitis C virus infection in the United States

The latest issue of the Annals of Internal Medicine makes predictions on the changing burden of Hepatitis C virus infection.

News image

fiogf49gjkf04

Chronic hepatitis C virus (HCV) infection causes a substantial health and economic burden in the United States. With the availability of direct-acting antiviral agents, recently approved therapies and those under development, and 1-time birth-cohort screening, the burden of this disease is expected to decrease.

Dr Chhatwal and colleagues from Texas, USA predicted the effect of new therapies and screening on chronic HCV infection and associated disease outcomes.

The research team evaluated existing and anticipated therapies and screening for HCV infection in the United States.

The team assessed the total HCV-infected population in the United States.

Outcomes included the number of cases of chronic HCV infection and outcomes of advanced-stage HCV infection.
Chronic HCV cases decreased from 3.2 million in 2001 to 2.3 million in 2013
Annals of Internal Medicine

The number of cases of chronic HCV infection decreased from 3.2 million in 2001 to 2.3 million in 2013.

The researchers report that 1-time birth-cohort screening beginning in 2013 is expected to identify 487,000 cases of HCV infection in the next 10 years.

In contrast, 1-time universal screening could identify 933,700 cases.

With the availability of highly effective therapies, HCV infection could become a rare disease in the next 22 years.

The team found that recently approved therapies for HCV infection and 1-time birth-cohort screening could prevent approximately 124,200 cases of decompensated cirrhosis, 78,800 cases of hepatocellular carcinoma, 126,500 liver-related deaths, and 9900 liver transplantations by 2050.

Increasing the treatment capacity would further reduce the burden of HCV disease.

Dr Chhatwal's team concludes, "New therapies for HCV infection and widespread implementation of screening and treatment will play an important role in reducing the burden of HCV disease."

"More aggressive screening recommendations are needed to identify a large pool of infected patients."

Ann Intern Med 2014; 161(3): 170-180
06 August 2014

Go to top of page Email this page Email this page to a colleague

 24 March 2017 
Prevalence of undiagnosed celiac disease
 24 March 2017 
MRI for local staging of colon cancer
 24 March 2017 
In-office communication about ulcerative colitis
 23 March 2017 
H. pylori and GERD in children
 23 March 2017 
Prespectives on the management of fecal incontinence
 23 March 2017 
Suspected nonceliac gluten sensitivity
 22 March 2017 
Abdominal visceral fat and new erosive esophagitis
 22 March 2017 
Role of microbiota in colorectal surgery
 22 March 2017 
Disease activity in eosinophilic esophagitis
 21 March 2017 
Hepatitis C virus–related hepatic myelopathy
 21 March 2017 
Global trends in colorectal cancer mortality
 21 March 2017 
Pain in pancreatic cancer
 20 March 2017 
Metastasis in human colorectal cancer
 20 March 2017 
Fistula treatment of Crohn’s disease
 20 March 2017 
NASH treatment and MRI
 17 March 2017 
Acute liver failure in Scotland
 17 March 2017 
Microbiota in colorectal cancer 
 17 March 2017 
Among Persons with IBD
 16 March 2017 
Hepatocellular carcinoma risk in different etiologies of cirrhosis
 16 March 2017 
IBD disability index
 16 March 2017 
Transition readiness scores in adolescents with IBD
 15 March 2017 
European consensus on fecal microbiota transplantation 
 15 March 2017 
Hepatocellular carcinoma in the USA 
 15 March 2017 
Hospital readmission for ulcerative colitis
 14 March 2017 
Cardiovascular diseases risk in Barrett's
 14 March 2017 
Assessment of competence in colonoscopy
 14 March 2017 
Cholecystectomy to prevent recurrent pancreatitis
 13 March 2017 
Gallstone disease after colectomy for ulcerative colitis
 13 March 2017 
Achalasia in Chicago since high-resolution manometry
 13 March 2017 
Vedolizumab exposure in pregnancy
 10 March 2017 
Thiopurine therapy in IBD
 10 March 2017 
Complications in advanced fibrosis in Hep C eradication
 10 March 2017 
Intragastric balloons for obesity-related co-morbidities
 09 March 2017 
Intestinal tuberculosis vs Crohn's disease
 09 March 2017 
Predictors of relapse in children with IBD
 09 March 2017 
Direct-acting antiviral regimen for Hep C genotype 3 
 08 March 2017 
Sterile fecal filtrate transfer for C. diff
 08 March 2017 
Drug-induced liver injury
 08 March 2017 
Pharmacotherapy for alcohol dependence
 07 March 2017 
Psychotropic drugs in functional dyspepsia
 07 March 2017 
Vagus nerve and appetite regulation
 07 March 2017 
Gastrointestinal involvement in systemic sclerosis
 06 March 2017 
Small bowel abnormalities in IBS 
 06 March 2017 
Treatment response in NASH with MRI
 06 March 2017 
Intestinal bacterial overgrowth and PPIs in children
 03 March 2017 
Alcohol and risk of gallstone disease
 03 March 2017 
Smoking at colon cancer diagnosis influences survival
 03 March 2017 
Improvements in Crohn’s Disease outcomes over time
 02 March 2017 
Surviving sepsis guidelines
 02 March 2017 
Tenofovir and Hep B transmission in pregnancy
 02 March 2017 
Diagnosis of pediatric IBD 
 01 March 2017 
Healthcare utilization amonth IBD Veterans
 01 March 2017 
Complications after ileocecal resection in Crohn’s
 01 March 2017 
Fecal microbiotica transplnantation

 28 February 2017 
Smoking and cancer-specific survival in colon cancer
 28 February 2017 
ALT levels and all-cause mortality
 28 February 2017 
American Gastroenterological Association for acute liver failure
 27 February 2017 
Hep B cure research
 27 February 2017 
Elemental diet in adult eosinophilic esophagitis patients
 27 February 2017 
Eluxadoline in IBS-diarrhea

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us